Ezrin Self-association Involves Binding of an N-terminal Domain to a Normally Masked C-terminal Domain That Includes the F-actin Binding Site
Overview
Molecular Biology
Authors
Affiliations
Ezrin is a membrane-cytoskeletal linking protein that is concentrated in actin-rich surface structures. It is closely related to the microvillar proteins radixin and moesin and to the tumor suppressor merlin/schwannomin. Cell extracts contain ezrin dimers and ezrin-moesin heterodimers in addition to monomers. Truncated ezrin fusion proteins were assayed by blot overlay to determine which regions mediate self-association. Here we report that ezrin self-association occurs by head-to-tail joining of distinct N-terminal and C-terminal domains. It is likely that these domains, termed N- and C-ERMADs (ezrin-radixin-moesin association domain), are responsible for homotypic and heterotypic associations among ERM family members. The N-ERMAD of ezrin resided within amino acids 1-296; deletion of 10 additional residues resulted in loss of activity. The C-ERMAD was mapped to the last 107 amino acids of ezrin, residues 479-585. The two residues at the C-terminus were required for activity, and the region from 530-585 was insufficient. The C-ERMAD was masked in the native monomer. Exposure of this domain required unfolding ezrin with sodium dodecyl sulfate or expressing the domain as part of a truncated protein. Intermolecular association could not occur unless the C-ERMAD had been made accessible to its N-terminal partner. It can be inferred that dimerization in vivo requires an activation step that exposes this masked domain. The conformationally inaccessible C-terminal region included the F-actin binding site, suggesting that this activity is likewise regulated by masking.
TNIK: A redox sensor in endothelial cell permeability.
Joachim J, Maselli D, Petsolari E, Aman J, Swiatlowska P, Killock D Sci Adv. 2024; 10(51):eadk6583.
PMID: 39705357 PMC: 11661440. DOI: 10.1126/sciadv.adk6583.
A bipartite NLS motif mediates the nuclear import of moesin.
Kovacs Z, Bajusz C, Szabo A, Borkuti P, Vedelek B, Benke R Front Cell Dev Biol. 2024; 12:1206067.
PMID: 38450250 PMC: 10915024. DOI: 10.3389/fcell.2024.1206067.
Lombardo A, Mitchell C, Zaman R, McDermitt D, Bretscher A Elife. 2024; 13.
PMID: 38193818 PMC: 10830128. DOI: 10.7554/eLife.83526.
Ali M, Khramushin A, Yadav V, Schueler-Furman O, Ivarsson Y Biochemistry. 2023; 62(11):1594-1607.
PMID: 37224425 PMC: 10249358. DOI: 10.1021/acs.biochem.3c00096.
The genetic landscape and possible therapeutics of neurofibromatosis type 2.
Ghalavand M, Asghari A, Farhadi M, Taghizadeh-Hesary F, Garshasbi M, Falah M Cancer Cell Int. 2023; 23(1):99.
PMID: 37217995 PMC: 10204202. DOI: 10.1186/s12935-023-02940-8.